Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.28
TFX's Cash to Debt is ranked lower than
83% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. TFX: 0.28 )
Ranked among companies with meaningful Cash to Debt only.
TFX' s 10-Year Cash to Debt Range
Min: 0.06  Med: 0.21 Max: 0.93
Current: 0.28
0.06
0.93
Equity to Asset 0.47
TFX's Equity to Asset is ranked lower than
74% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. TFX: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
TFX' s 10-Year Equity to Asset Range
Min: 0.32  Med: 0.47 Max: 0.53
Current: 0.47
0.32
0.53
Interest Coverage 4.35
TFX's Interest Coverage is ranked lower than
91% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. TFX: 4.35 )
Ranked among companies with meaningful Interest Coverage only.
TFX' s 10-Year Interest Coverage Range
Min: 2.18  Med: 4.57 Max: 9.07
Current: 4.35
2.18
9.07
F-Score: 6
Z-Score: 2.50
M-Score: -2.64
WACC vs ROIC
9.74%
9.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 15.92
TFX's Operating margin (%) is ranked higher than
83% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. TFX: 15.92 )
Ranked among companies with meaningful Operating margin (%) only.
TFX' s 10-Year Operating margin (%) Range
Min: -6.28  Med: 10.68 Max: 16.28
Current: 15.92
-6.28
16.28
Net-margin (%) 10.44
TFX's Net-margin (%) is ranked higher than
79% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. TFX: 10.44 )
Ranked among companies with meaningful Net-margin (%) only.
TFX' s 10-Year Net-margin (%) Range
Min: -12.25  Med: 6.17 Max: 21.66
Current: 10.44
-12.25
21.66
ROE (%) 9.87
TFX's ROE (%) is ranked higher than
69% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.14 vs. TFX: 9.87 )
Ranked among companies with meaningful ROE (%) only.
TFX' s 10-Year ROE (%) Range
Min: -10.11  Med: 12.33 Max: 21.44
Current: 9.87
-10.11
21.44
ROA (%) 4.71
TFX's ROA (%) is ranked higher than
65% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: -0.22 vs. TFX: 4.71 )
Ranked among companies with meaningful ROA (%) only.
TFX' s 10-Year ROA (%) Range
Min: -4.96  Med: 5.85 Max: 8.55
Current: 4.71
-4.96
8.55
ROC (Joel Greenblatt) (%) 35.20
TFX's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. TFX: 35.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TFX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13.25  Med: 21.43 Max: 35.77
Current: 35.2
-13.25
35.77
Revenue Growth (3Y)(%) 2.70
TFX's Revenue Growth (3Y)(%) is ranked lower than
52% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. TFX: 2.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TFX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -11  Med: 2.90 Max: 17.3
Current: 2.7
-11
17.3
EBITDA Growth (3Y)(%) 5.30
TFX's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. TFX: 5.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TFX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -7.8  Med: 4.90 Max: 15.4
Current: 5.3
-7.8
15.4
EPS Growth (3Y)(%) 12.20
TFX's EPS Growth (3Y)(%) is ranked higher than
65% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. TFX: 12.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TFX' s 10-Year EPS Growth (3Y)(%) Range
Min: -17.4  Med: 6.75 Max: 16.1
Current: 12.2
-17.4
16.1
» TFX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

TFX Guru Trades in Q2 2014

Joel Greenblatt 17,351 sh (+49.54%)
Jim Simons 375,400 sh (+13.80%)
Chuck Royce 309,700 sh (unchged)
Murray Stahl 6,679 sh (unchged)
John Keeley 3,820 sh (unchged)
Robert Olstein 63,000 sh (-3.08%)
Paul Tudor Jones 2,800 sh (-3.45%)
Third Avenue Management 270,465 sh (-26.84%)
Manning & Napier Advisors, Inc 2,190 sh (-99.79%)
» More
Q3 2014

TFX Guru Trades in Q3 2014

Joel Greenblatt 284,633 sh (+1540.44%)
Paul Tudor Jones 3,556 sh (+27.00%)
Robert Olstein 63,000 sh (unchged)
Chuck Royce 309,700 sh (unchged)
John Keeley 3,820 sh (unchged)
Manning & Napier Advisors, Inc 2,190 sh (unchged)
Jim Simons 360,000 sh (-4.10%)
Murray Stahl 6,384 sh (-4.42%)
Third Avenue Management 175,094 sh (-35.26%)
» More
Q4 2014

TFX Guru Trades in Q4 2014

Paul Tudor Jones 6,731 sh (+89.29%)
Jim Simons 546,400 sh (+51.78%)
Joel Greenblatt 359,093 sh (+26.16%)
Manning & Napier Advisors, Inc 2,190 sh (unchged)
Chuck Royce 309,700 sh (unchged)
Murray Stahl 6,384 sh (unchged)
John Keeley 3,070 sh (-19.63%)
Third Avenue Management 56,069 sh (-67.98%)
Robert Olstein 8,000 sh (-87.30%)
» More
Q1 2015

TFX Guru Trades in Q1 2015

Steven Cohen 190,268 sh (New)
Chuck Royce 344,900 sh (+11.37%)
John Keeley 3,170 sh (+3.26%)
Third Avenue Management 56,069 sh (unchged)
Robert Olstein Sold Out
Manning & Napier Advisors, Inc Sold Out
Murray Stahl 6,076 sh (-4.82%)
Jim Simons 450,100 sh (-17.62%)
Paul Tudor Jones 5,127 sh (-23.83%)
Joel Greenblatt 257,438 sh (-28.31%)
» More
» Details

Insider Trades

Latest Guru Trades with TFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 34.01
TFX's P/E(ttm) is ranked lower than
60% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 28.40 vs. TFX: 34.01 )
Ranked among companies with meaningful P/E(ttm) only.
TFX' s 10-Year P/E(ttm) Range
Min: 4.99  Med: 18.48 Max: 258.41
Current: 34.01
4.99
258.41
Forward P/E 19.05
TFX's Forward P/E is ranked higher than
57% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.26 vs. TFX: 19.05 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 33.20
TFX's PE(NRI) is ranked lower than
60% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 28.30 vs. TFX: 33.20 )
Ranked among companies with meaningful PE(NRI) only.
TFX' s 10-Year PE(NRI) Range
Min: 13.8  Med: 28.41 Max: 74.07
Current: 33.2
13.8
74.07
P/B 3.26
TFX's P/B is ranked lower than
51% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. TFX: 3.26 )
Ranked among companies with meaningful P/B only.
TFX' s 10-Year P/B Range
Min: 1.04  Med: 1.80 Max: 3.23
Current: 3.26
1.04
3.23
P/S 3.55
TFX's P/S is ranked lower than
55% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. TFX: 3.55 )
Ranked among companies with meaningful P/S only.
TFX' s 10-Year P/S Range
Min: 0.71  Med: 1.61 Max: 3.53
Current: 3.55
0.71
3.53
PFCF 29.41
TFX's PFCF is ranked higher than
53% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 30.88 vs. TFX: 29.41 )
Ranked among companies with meaningful PFCF only.
TFX' s 10-Year PFCF Range
Min: 5.92  Med: 12.79 Max: 51.16
Current: 29.41
5.92
51.16
POCF 22.30
TFX's POCF is ranked lower than
52% of the 149 Companies
in the Global Medical Devices industry.

( Industry Median: 21.63 vs. TFX: 22.30 )
Ranked among companies with meaningful POCF only.
TFX' s 10-Year POCF Range
Min: 5.23  Med: 10.86 Max: 27.24
Current: 22.3
5.23
27.24
EV-to-EBIT 22.45
TFX's EV-to-EBIT is ranked lower than
51% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 21.84 vs. TFX: 22.45 )
Ranked among companies with meaningful EV-to-EBIT only.
TFX' s 10-Year EV-to-EBIT Range
Min: -39.5  Med: 15.90 Max: 25.1
Current: 22.45
-39.5
25.1
Shiller P/E 42.01
TFX's Shiller P/E is ranked lower than
64% of the 94 Companies
in the Global Medical Devices industry.

( Industry Median: 30.75 vs. TFX: 42.01 )
Ranked among companies with meaningful Shiller P/E only.
TFX' s 10-Year Shiller P/E Range
Min: 10.33  Med: 19.59 Max: 41.81
Current: 42.01
10.33
41.81
Current Ratio 1.61
TFX's Current Ratio is ranked lower than
74% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. TFX: 1.61 )
Ranked among companies with meaningful Current Ratio only.
TFX' s 10-Year Current Ratio Range
Min: 1.46  Med: 2.04 Max: 5.2
Current: 1.61
1.46
5.2
Quick Ratio 1.10
TFX's Quick Ratio is ranked lower than
74% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. TFX: 1.10 )
Ranked among companies with meaningful Quick Ratio only.
TFX' s 10-Year Quick Ratio Range
Min: 0.86  Med: 1.29 Max: 4.01
Current: 1.1
0.86
4.01
Days Inventory 142.72
TFX's Days Inventory is ranked lower than
54% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 131.01 vs. TFX: 142.72 )
Ranked among companies with meaningful Days Inventory only.
TFX' s 10-Year Days Inventory Range
Min: 74.32  Med: 121.53 Max: 171.38
Current: 142.72
74.32
171.38
Days Sales Outstanding 56.79
TFX's Days Sales Outstanding is ranked higher than
68% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.21 vs. TFX: 56.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
TFX' s 10-Year Days Sales Outstanding Range
Min: 54.3  Med: 74.21 Max: 98.44
Current: 56.79
54.3
98.44

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.99
TFX's Dividend Yield is ranked lower than
71% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 1.64 vs. TFX: 0.99 )
Ranked among companies with meaningful Dividend Yield only.
TFX' s 10-Year Dividend Yield Range
Min: 0.99  Med: 1.91 Max: 3.48
Current: 0.99
0.99
3.48
Dividend Payout 0.33
TFX's Dividend Payout is ranked higher than
56% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 0.39 vs. TFX: 0.33 )
Ranked among companies with meaningful Dividend Payout only.
TFX' s 10-Year Dividend Payout Range
Min: 0.06  Med: 0.27 Max: 2.13
Current: 0.33
0.06
2.13
Yield on cost (5-Year) 1.00
TFX's Yield on cost (5-Year) is ranked lower than
68% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. TFX: 1.00 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TFX' s 10-Year Yield on cost (5-Year) Range
Min: 0.99  Med: 1.91 Max: 3.48
Current: 1
0.99
3.48
Share Buyback Rate -4.40
TFX's Share Buyback Rate is ranked lower than
52% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: -4.00 vs. TFX: -4.40 )
Ranked among companies with meaningful Share Buyback Rate only.
TFX' s 10-Year Share Buyback Rate Range
Min: 1  Med: -0.80 Max: -4.4
Current: -4.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.18
TFX's Price/Projected FCF is ranked lower than
54% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. TFX: 2.18 )
Ranked among companies with meaningful Price/Projected FCF only.
TFX' s 10-Year Price/Projected FCF Range
Min: 0.47  Med: 1.11 Max: 2.88
Current: 2.18
0.47
2.88
Price/Median PS Value 2.19
TFX's Price/Median PS Value is ranked lower than
87% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 1.14 vs. TFX: 2.19 )
Ranked among companies with meaningful Price/Median PS Value only.
TFX' s 10-Year Price/Median PS Value Range
Min: 0.45  Med: 0.69 Max: 1.93
Current: 2.19
0.45
1.93
Earnings Yield (Greenblatt) (%) 4.47
TFX's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. TFX: 4.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TFX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 4  Med: 6.00 Max: 9.8
Current: 4.47
4
9.8
Forward Rate of Return (Yacktman) (%) 1.21
TFX's Forward Rate of Return (Yacktman) (%) is ranked lower than
58% of the 99 Companies
in the Global Medical Devices industry.

( Industry Median: 4.14 vs. TFX: 1.21 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TFX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 3.1  Med: 6.70 Max: 20.9
Current: 1.21
3.1
20.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:TBH.Germany,
Teleflex Inc is a Delaware Corporation incorporated in 1943. The Company is a provider of medical technology products that provides clinical benefits, improve patient and provider safety and reduce total procedural costs. It designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It sells its products to hospitals and healthcare providers in more than 150 countries through a combination of its direct sales force and distributors. The Company manufactures its products at 27 manufacturing sites, with major manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. It provides a broad-based platform of products, which it categorizes into four groups namely Critical Care, Surgical Care, Cardiac Care and OEM and Development Services. It is a provider of specialty products for critical care, which is predominantly comprised of single-use products. The large majority of sales for single-use products are made to the hospital/healthcare provider market, with a smaller percentage sold to alternate sites. The Company's surgical products include ligation and closure products, including appliers, clips and sutures used in a variety of surgical procedures; access ports used in minimally invasive surgical procedures, including robotic surgery; and fluid management products used for chest drainage. The Company's surgical products also include hand-held instruments for general and specialty surgical procedures. It markets surgical products under the Deknatel, Pleur-evac, Pilling, Taut and Weck brand names. Products in Cardiac Care category include diagnostic catheters and capital equipment. The Company's diagnostic catheters include thermodilution and wedge pressure catheters; specialized angiographic catheters, such as Berman and Reverse Berman catheters; therapeutic delivery catheters, such as temporary pacing catheters; sheaths for femoral and trans-radial aortic access used in diagnostic and therapeutic procedures; and intra-aortic balloon, or IAB, catheters. Capital equipment includes its intra-aortic balloon pump, or IABP, consoles. IABP products are used to augment oxygen delivery to the cardiac muscle and reduce the oxygen demand after cardiac surgery, serious heart attack or interventional procedures. The IAB and IABP product lines feature the AutoCAT 2 WAVE console and the FiberOptix catheter, which together utilize fiber optic technology for arterial pressure signal acquisition and enable the patented WAVE timing algorithm to support the broadest range of patient heart rhythms, including severely arrhythmic patients. The Company's OEM division, which includes the TFX OEM(r) and Deknatel(r) OEM nameplates, provides custom-engineered extrusions, diagnostic and interventional catheters, sheath/dilator sets (introducers) and kits, sutures, perfo
» More Articles for TFX

Headlines

Articles On GuruFocus.com
Teleflex Declares Its Quarter Four Results Feb 24 2015 
Third Avenue Management Update Aug 31 2013 
My Dividend Portfolio Looks Much Better than I Expected Jun 03 2013 
Teleflex Incorporated: Successful Transition into Pure-Play Medical Device Manufacturer Nov 19 2012 
5 Healthcare Stocks You Should Know About Mar 31 2012 
Teleflex: High Upside Potential This Year Mar 27 2012 
5 Healthcare Stocks to Consider for 2012 Mar 27 2012 
Third Avenue Management Buys Lowes, Teleflex, American Eagle Outfitters, Tellabs, Sells Pharmaceutic Nov 17 2011 
Teleflex Inc. Reports Operating Results (10-Q) Oct 27 2010 
Teleflex Inc. Reports Operating Results (10-Q) Jul 23 2010 

More From Other Websites
Intuitive Surgical, Inc. Earnings Analysis: By the Numbers Jul 27 2015
Teleflex Announces Second Quarter 2015 Earnings Conference Call Information Jul 16 2015
Teleflex Announces Second Quarter 2015 Earnings Conference Call Information Jul 16 2015
Teleflex Hits 52-Week High on Strong Q1, Outlook Favorable - Analyst Blog Jun 09 2015
Teleflex to Present at the 20th European Hematology Association (EHA) Congress Jun 09 2015
Teleflex to Present at the 20th European Hematology Association (EHA) Congress Jun 09 2015
TELEFLEX INC Files SEC form 8-K, Other Events Jun 03 2015
Teleflex to Showcase Key Anaesthesia Products at Euroanaesthesia 2015 (“ESA”) in Berlin May 28 2015
Teleflex to Showcase Key Anaesthesia Products at Euroanaesthesia 2015 (“ESA”) in Berlin May 28 2015
Teleflex to Present at William Blair 35th Annual Growth Stock Conference May 27 2015
Teleflex to Present at William Blair 35th Annual Growth Stock Conference May 27 2015
Teleflex to Present at the 52nd European Renal, Dialysis and Transplant Congress (ERA-EDTA) May 26 2015
Teleflex to Present at the 52nd European Renal, Dialysis and Transplant Congress (ERA-EDTA) May 26 2015
Teleflex to Present at the 52nd European Renal, Dialysis and Transplant Congress (ERA-EDTA) May 26 2015
3 Medical Device Stocks to Buy Right Now May 26 2015
Teleflex Upholds FY15 View, Issues 2016-18 Outlook - Analyst Blog May 22 2015
Teleflex Incorporated Hosts Investor and Analyst Day May 21 2015
TELEFLEX INC Files SEC form 8-K, Regulation FD Disclosure May 21 2015
Teleflex Incorporated Hosts Investor and Analyst Day May 21 2015
Teleflex Incorporated to Host Investor and Analyst Day May 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK